Christopher W. Schmidt

List of Publications by Year
in descending order

61	4,066	109321	123424
papers	citations	35 h-index	61 g-index

62	62	62	6313
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma. Nature, 2011, 480, 99-103.	27.8	413
2	Dominant selection of an invariant T cell antigen receptor in response to persistent infection by Epstein-Barr virus.. Journal of Experimental Medicine, 1994, 180, 2335-2340.	8.5	290
3	Deep sequencing of uveal melanoma identifies a recurrent mutation in PLCB4. Oncotarget, 2016, 7, 4624-4631.	1.8	235
4	Characterization of the Melanoma miRNAome by Deep Sequencing. PLoS ONE, 2010, 5, e9685.	2.5	181
5	An Epstein-Barr virus-specific cytotoxic T cell epitope in EBV nuclear antigen 3 (EBNA 3).. Journal of Experimental Medicine, 1990, 171, 345-349.	8.5	175
6	Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/dendritic cell vaccine. Cancer Immunology, Immunotherapy, 2003, 52, 387-395.	4.2	175
7	Frequent somatic mutations in MAP3K5 and MAP3K9 in metastatic melanoma identified by exome sequencing. Nature Genetics, 2012, 44, 165-169.	21.4	170
8	Microarray expression profiling in melanoma reveals a BRAF mutation signature. Oncogene, 2004, 23, 4060-4067.	5.9	169
9	A Galectin-3 Ligand Corrects the Impaired Function of Human CD4 and CD8 Tumor-Infiltrating Lymphocytes and Favors Tumor Rejection in Mice. Cancer Research, 2010, 70, 7476-7488.	0.9	149
10	Antigens for cancer immunotherapy. Seminars in Immunology, 2008, 20, 286-295.	5.6	147
11	Breast cancer stem cells: implications for therapy of breast cancer. Breast Cancer Research, 2008, 10, 210.	5.0	109
12	A case report: Immune responses and clinical course of the first human use of granulocyte/macrophage-colony-stimulating-factor-transduced autologous melanoma cells for immunotherapy. Cancer Immunology, Immunotherapy, 1997, 44, 10-20.	4.2	101
13	Temozolomide- and fotemustine-induced apoptosis in human malignant melanoma cells: response related to MGMT, MMR, DSBs, and p53. British Journal of Cancer, 2009, 100, 322-333.	6.4	90
14	Whole genome landscapes of uveal melanoma show an ultraviolet radiation signature in iris tumours. Nature Communications, 2020, 11, 2408.	12.8	86
15	miR-514a regulates the tumour suppressor NF1 and modulates BRAFi sensitivity in melanoma. Oncotarget, 2015, 6, 17753-17763.	1.8	81
16	Numerical and functional defects of blood dendritic cells in early- and late-stage breast cancer. British Journal of Cancer, 2007, 97, 1251-1259.	6.4	74
17	Results of a phase I dendritic cell vaccine trial for malignant astrocytoma: potential interaction with adjuvant chemotherapy. Journal of Clinical Neuroscience, 2008, 15, 114-121.	1.5	74
18	Cross-Platform Array Screening Identifies COL1A2, THBS1, TNFRSF10D and UCHL1 as Genes Frequently Silenced by Methylation in Melanoma. PLoS ONE, 2011, 6, e26121.	2.5	73

#	Article	IF	Citations
19	Crossreactive recognition of viral, self, and bacterial peptide ligands by human class I-restricted cytotoxic T lymphocyte clonotypes: Implications for molecular mimicry in autoimmune disease. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 2279-2284.	7.1	68
20	Lentiviral Vector-Mediated Tyrosinase-Related Protein 2 Gene Transfer to Dendritic Cells for the Therapy of Melanoma. Human Gene Therapy, 2001, 12, 2203-2213.	2.7	66
21	A functional link for major TCR expansions in healthy adults caused by persistent Epstein-Barr virus infection.. Journal of Clinical Investigation, 1998, 102, 1551-1558.	8.2	62
22	A Population of HLA-DR+ Immature Cells Accumulates in the Blood Dendritic Cell Compartment of Patients with Different Types of Cancer. Neoplasia, 2005, 7, 1112-1122.	5.3	60
23	Treatment of non-resectable hepatocellular carcinoma with autologous tumor-pulsed dendritic cells. Journal of Gastroenterology and Hepatology (Australia), 2002, 17, 889-896.	2.8	59
24	In Vitro Analysis of Breast Cancer Cell Line Tumourspheres and Primary Human Breast Epithelia Mammospheres Demonstrates Inter- and Intrasphere Heterogeneity. PLoS ONE, 2013, 8, e64388.	2.5	55
25	Strategies Involved in Developing an Effective Vaccine for EBV-Associated Diseases. Advances in Cancer Research, 1996, 69, 213-245.	5.0	52
26	Exome Sequencing to Predict Neoantigens in Melanoma. Cancer Immunology Research, 2015, 3, 992-998.	3.4	50
27	Melanomas of unknown primary have a mutation profile consistent with cutaneous sunâ€exposed melanoma. Pigment Cell and Melanoma Research, 2013, 26, 852-860.	3.3	48
28	Dendritic cell immunotherapy for stage IV melanoma. Melanoma Research, 2007, 17, 316-322.	1.2	46
29	Spontaneous apoptosis of blood dendritic cells in patients with breast cancer. Breast Cancer Research, 2005, 8, R5.	5.0	45
30	A High-Throughput Panel for Identifying Clinically Relevant Mutation Profiles in Melanoma. Molecular Cancer Therapeutics, 2012, 11, 888-897.	4.1	45
31	In vitro anti-tumour activity of Î±-galactosylceramide-stimulated human invariant VÎ±24+NKT cells against melanoma. British Journal of Cancer, 2001, 85, 741-746.	6.4	44
32	Sequence variation of cytotoxic T cell epitopes in different isolates of Epstein-Barr virus. European Journal of Immunology, 1992, 22, 183-189.	2.9	43
33	Small-molecule Bcl-2 inhibitors sensitise tumour cells to immune-mediated destruction. British Journal of Cancer, 2007, 96, 600-608.	6.4	43
34	Recruitment during Infectious Mononucleosis of CD3+CD4+CD8+Virus-Specific Cytotoxic T Cells Which Recognise Epsteinâ€“Barr Virus Lytic Antigen BHRF1. Virology, 1996, 219, 489-492.	2.4	41
35	Immunostimulatory cancer chemotherapy using local ingenol-3-angelate and synergy with immunotherapies. Vaccine, 2009, 27, 3053-3062.	3.8	35
36	Nonresponsiveness to an immunodominant Epstein-Barr virus-encoded cytotoxic T-lymphocyte epitope in nuclear antigen 3A: implications for vaccine strategies.. Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 9478-9482.	7.1	33

#	Article	IF	Citations
37	Exploration of peptides bound to <scp>MHC</scp> class I molecules in melanoma. Pigment Cell and Melanoma Research, 2015, 28, 281-294.	3.3	31
38	Melanoma vaccines: developments over the past 10 years. Expert Review of Vaccines, 2011, 10, 853-873.	4.4	27
39	Composite response of naive T cells to stimulation with the autologous lymphoblastoid cell line is mediated by CD4 cytotoxic T cell clones and includes an Epstein-Barr virus-specific component. Cellular Immunology, 1991, 132, 295-307.	3.0	25
40	Identification of TFG (TRKâ€fused gene) as a putative metastatic melanoma tumor suppressor gene. Genes Chromosomes and Cancer, 2012, 51, 452-461.	2.8	25
41	The Labyrinthine Ways of Cancer Immunotherapyâ€"T Cell, Tumor Cell Encounter: â€œHow Do I Lose Thee? Let Me Count the Waysâ€• Advances in Cancer Research, 1998, 75, 203-249.	5.0	23
42	Effect of pre-existing cytotoxic T lymphocytes on therapeutic vaccines. European Journal of Immunology, 2000, 30, 671-677.	2.9	22
43	The ecology and pathology of Epsteinâ€Barr virus. Immunology and Cell Biology, 1995, 73, 489-504.	2.3	21
44	Tumor metastasis biopsy as a surrogate marker of response to melanoma immunotherapy. Pathology, 1999, 31, 116-122.	0.6	20
45	Immunological characteristics correlating with clinical response to immunotherapy in patients with advanced metastatic melanoma. Immunology and Cell Biology, 2006, 84, 295-302.	2.3	20
46	Generation of CD8⁺T cells expressing two additional T-cell receptors (TETARs) for personalised melanoma therapy. Cancer Biology and Therapy, 2015, 16, 1323-1331.	3.4	20
47	Dominant Cytotoxic T Lymphocyte Response to the Immediateâ€EarlyTransâ€•Activator Protein, BZLF1, in Persistent Type A or B Epsteinâ€Barr Virus Infection. Journal of Infectious Diseases, 1997, 176, 1068-1072.	4.0	19
48	Dendritic cell immunotherapy for breast cancer. Expert Opinion on Biological Therapy, 2006, 6, 591-604.	3.1	18
49	HLA-DR+ Immature Cells Exhibit Reduced Antigen-Presenting Cell Function But Respond to CD40 Stimulation. Neoplasia, 2005, 7, 1123-1132.	5.3	15
50	MHC class I-restricted exogenous presentation of a synthetic 102-mer malaria vaccine polypeptide. European Journal of Immunology, 2005, 35, 681-689.	2.9	14
51	The key role of CD40 ligand in overcoming tumor-induced dendritic cell dysfunction. Breast Cancer Research, 2006, 8, 402.	5.0	13
52	Cytotoxic T lymphocyte discrimination between type A Epstein–Barr virus transformants is mapped to an immunodominant epitope in EBNA 3. Journal of General Virology, 1991, 72, 405-409.	2.9	11
53	IMMUNOTHERAPY, INCLUDING GENE THERAPY, FOR METASTATIC MELANOMA. ANZ Journal of Surgery, 1997, 67, 834-841.	0.7	9
54	Patterns of reactivity of Epstein-Barr virus-specific T cells in A-type donor cultures after reactivation with autologous A- or B-type transformants. Cellular Immunology, 1990, 127, 47-55.	3.0	8

#	Article	IF	Citations
55	Lymphokine-activated killer (lak) cells discriminate between epstein-barr virus (ebv)-positive burkitt's lymphoma cells. International Journal of Cancer, 1990, 46, 399-404.	5.1	7
56	The value of MLA 144 culture fluid for the isolation of human immunodeficiency virus. Immunology and Cell Biology, 1989, 67, 147-149.	2.3	4
57	Oligopeptide Induction of a Secondary Cytotoxic T-cell Response to Epstein-Barr Virus In Vitro. Scandinavian Journal of Immunology, 1991, 33, 411-420.	2.7	4
58	Fulminant Infectious Mononucleosis and Recurrent Epsteinâ€Barr Virus Reactivation in an Adolescent. Clinical Infectious Diseases, 2010, 50, e34-e37.	5.8	4
59	High Efficiency Ex Vivo Cloning of Antigen-Specific Human Effector T Cells. PLoS ONE, 2014, 9, e110741.	2.5	4
60	Interleukin-2 receptors in infectious mononucleosis. Immunology Letters, 1989, 23, 139-142.	2.5	3
61	T lymphocytes in infectious mononucleosis; Effect of ILâ€2 on the outgrowth of Epsteinâ€Barr virusâ€infected cells. Immunology and Cell Biology, 1989, 67, 49-55.	2.3	0